Total
0
Shares
Actinogen Medical (ASX: ACW) - Chairman, Geoff Brooke
Chairman, Geoff Brooke
Source: Actinogen Medical
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Actinogen Medical (ACW) has gained FDA approval to proceed with a clinical trial under the investigational new drug application
  • The Phase 2 protocol will see around 50 patients with the genetic disorder Fragile X Syndrome treated using Xanamem over a 12-week period
  • A letter of intent to operationalise the trial has been signed by Worldwide Clinical Trials, with $944,724 granted to enable the activation of clinical sites
  • Actinogen Medical dropped 14.5 per cent, trading at 16.3 cents at 12:00 pm AEDT

Actinogen Medical (ACW) has gained FDA approval to proceed with a clinical trial under its Investigational New Drug (IND) application.

Actinogen is a biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol.

The company’s lead compound, Xanamem, has been investigated as a new therapy for Alzheimer’s Disease, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact.

The US Food and Drug Administration approved the company’s Phase 2 protocol, entitled “XanaFX: A Phase II Double-Blind, Randomized, Placebo Controlled trial, to Assess the Safety, Tolerability, and Efficacy of the 11β-HSD1 Inhibitor Xanamem in Treating Male Adolescents and Young Adults with Fragile X Syndrome.”

The Phase 2 protocol will see the genetic disorder Fragile X Syndrome treated using Xanamem. Around 50 patients will be enrolled over a 12-week treatment period, with results expected in 2023.

A letter of intent to operationalise the trial has been signed by Worldwide Clinical Trials, a research organisation specialising in neurological, paediatric, and rare diseases.

The sum of $944,724 for start-up activities has been granted to enable activation of clinical sites over a 60-day duration.

Actinogen Medical dropped 14.5 per cent, trading at 16.3 cents at 12:00 pm AEDT.

ACW by the numbers
More From The Market Herald
Raiz Invest (ASX:RZI) - CEO Australia & Group COO, Brendan Malone

" Raiz Invest (ASX:RZI) announces investment by Seven West Media (ASX:SWM)

Media giant Seven West Media (SWM) has taken an investment stake in Raiz (RZI), in order to accelerate the growth of the financial

" Frontier Resources (ASX:FNT) reports encouraging rock chip results

Frontier Resources (FNT) is reporting a number of encouraging results from a recent rock chip sampling program at its Gascoyne Project in Western

" Vection Technologies (ASX:VR1) announces $12m capital raise

Software company Vection Technologies (VR1) announced a $12 million capital raise to support its expansion plans and to strengthen its research and development
Galan Lithium (ASX:GLN) - MD, Juan Pablo Vargas de la Vega

" Galan Lithium (ASX:GLN) returns “excellent” assessment results from Candelas Project

Galan Lithium (GLN) said it has returned “excellent” preliminary economic assessment results from its Candelas Project in Catamarca, Argentina.